CRO signs vaccine research deal; Novavax prepares IIa flu trial;

Vaccine Research

The CRO Encorium has signed $6.2 million in new contracts to undertake new vaccine research work. Encorium release

Novavax has completed enrollment of healthy volunteers in a Phase IIa clinical trial of its virus-like particle based seasonal influenza vaccine. Novavax release

San Diego-based Inovio Biomedical has received a contract for $933,000 from the Department of Defense to continue research and development of DNA-based vaccines. Inovio release

Sinovac Biotech is launching new studies in China as it sets out to develop a vaccine against hand, foot and mouth disease, a childhood disease that is caused by human enterovirus 71. Sinovac release

Researchers in the U.S. say that new insights into immunity responses in humans could lead to a more effective pneumococcal vaccine. Story

Wyeth Pharmaceuticals has launched a community acquired pneumonia immunization trial in adults, studying an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia. Wyeth Release

Vaccine Market

The CDC is recommending that a record number of Americans get a flu shot this fall. And they've made sure that a record amount of flu vaccine will be on hand. Report

Fears that the MMR triple-shot vaccine could be linked to bowel problems and autism has persuaded a growing number of parents in the UK to avoid the jab for their kids. And as a result, the number of measles cases should break 1,000 for the first time in decades. Story

Twenty-two major medical groups in the U.S. have joined forces to spread the message that vaccines are safe. Report

A Catholic school in the UK is refusing to allow girls to get the HPV cancer vaccine on campus. Story

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.